Oncoinvent As
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Holding
- Established
- 2010-08-10
- Employees
- 11
- Market Cap
- -
- Website
- http://www.oncoinvent.com
Clinical Trials
5
Active:4
Completed:0
Trial Phases
2 Phases
Phase 1:4
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (80.0%)Phase 2
1 (20.0%)A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Oncoinvent AS
- Target Recruit Count
- 114
- Registration Number
- NCT06504147
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇧🇪UZ Leuven, Leuven, Belgium
🇳🇴The Norwegian Radiumhospital, Oslo, Norway
Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis
Phase 1
Active, not recruiting
- Conditions
- Peritoneal CarcinomatosisOvarian Cancer
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Oncoinvent AS
- Target Recruit Count
- 49
- Registration Number
- NCT03732768
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
🇳🇴The Norwegian Radiumhospital, Oslo, Norway
🇪🇸Clínica Universidad de Navarra, Pamplona, Spain
Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC
Phase 1
Active, not recruiting
- Conditions
- Peritoneal CarcinomaColorectal Carcinoma
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Oncoinvent AS
- Target Recruit Count
- 67
- Registration Number
- NCT03732781
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
🇸🇪Akademiska, Uppsala, Sweden
News
No news found